Increased regulatory activity of intestinal innate lymphoid cells type 3 (ILC3) prevents experimental autoimmune encephalomyelitis severity.

"Declarations Ethical approval and consent to participateEthical approval for the experiments was granted by the Veterinary Administration, of the Ministry of Agriculture, Forestry and Water Management, of the Republic of Serbia (No 323–07-01337/2020–05 and No 323–07-05815/2020–05/1). Consent for publicationNot applicable. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding This work was supported by the Ministry of Science, Technological Development, and Innovations, Republic of Serbia (Contract No. 451–03-47/2023–01/200007), by the Science Fund, Republic of Serbia, Ideas Program, project GUTtoAID (Contract No. 7742898), and by the European Federation of Immunological Societies (EFIS, 2021 Eastern Star Award). The work pertaining to the discovery and development of the Ffar2 agonist was supported by the Ministry of Sustainable Development and Public Works, Walloon Region, Belgium. For any questions and/or requests regarding the Ffar2 agonist (“Cpd1”), please contact Epics Therapeutics S.A. (Belgium) at info@epicstherapeutics.com."